Price
$373.29
Increased by +0.63%
Dollar Volume
83.37 M
ADR%
2.36
Market Cap.
20.68 B
Shares Float
54.93 M
Shares Outstanding
55.40 M
Beta
0.51
Price / Earnings
-32.38
BPR
207.89
20D Range
365.90 404.90
50D Range
364.63 407.93
200D Range
267.35 407.93
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Oct 27, 22 -4.26
Decreased by -315.15%
-3.41
Decreased by -24.93%
Jul 28, 22 -3.80
Decreased by -369.14%
-4.83
Increased by +21.33%
May 5, 22 -4.36
Decreased by -23.51%
-4.87
Increased by +10.47%
Oct 28, 21 -4.10
Decreased by -20.94%
-4.42
Increased by +7.24%
Jul 29, 21 1.98
Increased by +169.23%
-3.58
Increased by +155.31%
May 14, 21 -0.81
Increased by +56.68%
-3.13
Increased by +74.12%
Mar 4, 21 -3.53
Decreased by -48.95%
-2.64
Decreased by -33.71%
Oct 22, 20 -3.39
Decreased by -413.64%
-2.39
Decreased by -41.84%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 137.98 M
Increased by +16.00 K%
-235.04 M
Decreased by -0.61%
Decreased by -170.34%
Increased by +99.38%
Jun 30, 22 75.19 M
Decreased by -75.92%
-208.75 M
Decreased by -301.50%
Decreased by -277.61%
Decreased by -936.71%
Mar 31, 22 23.41 M
Decreased by -85.20%
-227.19 M
Decreased by -461.89%
Decreased by -970.39%
Decreased by -3.70 K%
Dec 31, 21 26.02 M
Increased by +126.89%
-237.82 M
Decreased by -50.84%
Decreased by -913.91%
Increased by +33.52%
Sep 30, 21 857.00 K
Decreased by -95.92%
-233.61 M
Decreased by -120.60%
Decreased by -27.26 K%
Decreased by -5.30 K%
Jun 30, 21 312.24 M
Increased by +3.96 K%
103.60 M
Increased by +508.72%
Increased by +33.18%
Increased by +110.06%
Mar 31, 21 158.16 M
Increased by +1.75 K%
-40.43 M
Increased by +31.33%
Decreased by -25.57%
Increased by +96.28%
Sep 30, 20 11.47 M
Decreased by -71.98%
-157.66 M
Decreased by -2.18 K%
Decreased by -1.37 K%
Decreased by -7.52 K%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.